Progress and trends in pediatric hematopoietic cell transplantation in Central-East European countries

Abstract

Hematopoietic cell transplantation (HCT) is widely used as a treatment for acquired and congenital disorders. In recent years, a significant increase in transplant activity around the world has been observed, especially in Eastern European countries. This article aimed to assess progress and trends in pediatric HCT in Central-Eastern European countries between 2013 and 2018. Transplant activity survey in 2013 and 2018 in nine Central-Eastern European countries (Czech Republic, Croatia, Hungary, Lithuania, Poland, Romania, Slovakia, Slovenia, and Ukraine) was performed. The highest transplant rates in total were found in the Czech Republic and Hungary. When calculated per 10 million of the pediatric population, a 25.9% increase in the number of allo-HCT was observed with the highest in Croatia, Romania, Lithuania, and Poland; and a 12.2% increase in the number of auto-HCT was observed with the highest in Slovenia, Slovakia, Romania, Poland, Ukraine, and Croatia. We have shown, over the years 2013 and 2018, in some countries of Central-Eastern Europe that there was a significant increase in transplant activity, especially in those with the lower rates. This increase was observed mainly in centers already existing in 2013, especially in the allo-HCT setting. The rise of activity was significantly less influenced by the creation of new transplant centers or the increase in the number of pediatric transplant beds. In conclusion, our analysis indicates that in the Czech Republic, Hungary, Lithuania, and Slovenia, the actual infrastructure and the number of HCTs cover the needs, whereas in other countries, especially in Romania and Ukraine, the number of HCT needs to be increased.

The impact of clonal hematopoiesis on outcomes in patients with aplastic anemia

“…As AA may be associated with PNH, detection of the PNH clone is more indicative for AA than any other cause of pancytopenia and bone marrow failure. Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered to be the only curative procedure for patients with severe aplastic anemia (SAA), it is recommended that younger patients, particularly children, undergo careful evaluation of concomitant illnesses and performance status to determine unfit or frail patients before intensive therapies, including allo-HSCT or immunosuppressive therapy (IST) [antithymocyte globulin (ATG) or cyclosporine A (CsA)], due to treatment-related mortality and morbidity [76][77][78]. Figure 1 shows a practical therapeutic algorithm in SAA [European Group for Blood and Marrow Transplantation (EBMT) algorithm for SAA in 2019, modified] [5].…”

Progress in molecular profiling: new recommendations in myelodysplastic syndromes

“…This will be followed by recommendations on MDS treatment to appear in the next issue of "Acta Haematologica Polonica" [3]. These recommendations are in line with our journal's policy of international cooperation in hematology [4][5][6][7][8][9][10].…”

“Acta Haematologica Polonica”: on its new road

“…A new year calls for new directions, but our fresh perspective is based on the substantial achievements of our Society, and the position of respect that we have earned [4][5][6][7].…”